Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).
Fiche publication
Date publication
juin 2024
Journal
Frontiers in endocrinology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ZANETTA Sylvie
Tous les auteurs :
Leboulleux S, Kapiteijn E, Litière S, Schöffski P, Godbert Y, Rodien P, Jarzab B, Salvatore D, Zanetta S, Capdevila J, Bastholt L, De La Fouchardiere C, Lalami Y, Bardet S, Cornélis F, Dedecjus M, Links T, Sents W, Schlumberger M, Locati DL, Newbold K
Lien Pubmed
Résumé
Nintedanib is a triple-angiokinase inhibitor with potential activity in patients with advanced thyroid cancers, as radioiodine refractory differentiated thyroid cancer (RAIR DTC) and medullary thyroid cancer (MTC).
Mots clés
MTC, RAIR DTC, nintedanib, phase II trial, triple-angiokinase inhibitor
Référence
Front Endocrinol (Lausanne). 2024 06 27;15:1403687